

Supplementary Table S1. Implant complications in anti-RNA polymerase III-positive vs. negative patients (total events).

Outcome	ARA positive (n = 19)	Negative patients (n = 29)	OR (95% CI)	p-value
Total events				
Rupture, n (%)	10 (52.6)	7 (24.1)	3.49 (1.05–11.57)	0.043
Axillary lymphadenopathy, n (%)	5 (26.3)	3 (10.3)	3.10 (0.70–13.78)	0.110
Infection, n (%)	2 (10.5)	1 (3.4)	3.29 (0.29–37.26)	0.390
Any complication, n (%)	12 (63.2)	8 (27.6)	4.50 (1.26–16.06)	0.013
Explant, n (%)	14 (73.7)	10 (34.5)	5.32 (1.58–17.89)	0.008
Reimplant, n (%)	7 (36.8)	5 (17.2)	2.80 (0.77–10.20)	0.176

Data are presented as n (%). Only patients with breast implants prior to systemic sclerosis onset were included. Total events include all recorded complications, including those with unknown timing.

Any complication includes rupture, axillary lymphadenopathy and infection.

Data on implant complications were unavailable for 10 patients.

Odds ratios were calculated from 2×2 contingency tables.

Supplementary Table S2. Characteristics of anti-RNA polymerase III-positive systemic sclerosis patients by breast implant and cancer status.

Variable	Breast implant only (n=19)	Synchronous cancer (n=8)	Non-synchronous cancer (n=32)	No implant/no cancer (n=250)	Overall p-value	Breast implant vs. synchronous p-value
SSc onset age, years, median [IQR]	44.2 [35.6–52.0]	57.5 [52.1–65.3]	51.3 [41.5–59.1]	49.0 [40.8–57.6]	0.063	0.011
Overlap syndrome, n (%)	3 (15.8)	1 (12.5)	3 (9.4)	36 (14.4)	0.900	1.000
Organ involvement						
ILD, n (%)	4 (21.1)	5 (62.5)	9 (28.1)	64 (25.6)	0.152	0.072
SRC, n (%)	4 (21.1)	2 (25.0)	6 (18.8)	53 (21.2)	0.974	1.000
PH, n (%)	2 (10.5)	0 (0.0)	2 (6.2)	12 (4.8)	0.513	1.000
Cardiac involvement, n (%)	0 (0.0)	2 (25.0)	1 (3.1)	12 (4.8)	0.110	0.080

Data are presented as n (%) unless otherwise indicated.

Synchronous cancer was defined as a diagnosis of cancer occurring within ±2 years of SSc onset. Non-synchronous cancer was defined as cancer diagnosed outside this time window.

Patients with breast implants and cancer diagnosed before SSc onset were excluded. Patients with breast implants after SSc onset and prior cancer were included in the cancer group.

No other significant differences were observed between the groups in pairwise comparisons (data not shown).

ILD: interstitial lung disease; PH: pulmonary hypertension; SRC: scleroderma renal crisis; SSc: systemic sclerosis.